Meda acquires OTC products

Meda acquires OTC products

Meda has acquired three well established OTC products from Norgine, a
Dutch pharma company. The products are Pyralvex (relief of pain
associated with e.g. aphthous ulcers), Spasmonal (treatment of for
example Irritable Bowel Syndrome) and Waxsol (ear drops). The largest
product is Pyralvex, which has a turnover of about 90 MSEK. Total annual
sales for the products are about 190 MSEK and the majority of sales are
generated in Europe. The purchase price is 540 MSEK which equals an
EBITDA* multiple of about 5.

”OTC products is a growing segment. This acquisition of well known OTC
brands further strengthens our presence in this area”, said Anders
Lönner, CEO Meda.

 

Note (*): EBITDA = Earnings before interest, taxes, depreciation, and
amortization.

For questions, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878